Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial
Retatrutide achieves 28.3% weight loss in Phase 3 obesity trial, significantly exceeding results from competing GLP-1 receptor agonists over...
Climb Bio’s CLYM116 Shows Clean Phase 1 Safety in IgAN Program
CLYM116 Phase 1 safety data shows all adverse events were Grade 1–2 and self-resolving in healthy volunteers dosed up...
Acmopatide Reduces A1C and Weight in Type 1 Diabetes Phase 2 Trial
Acmopatide reduces A1C and weight in Type 1 Diabetes Phase 2 Trial, offering potential insulin-sparing benefits in a 16-week...
Immutep’s IMP761 LAG-3 Agonist Meets Safety Goals in Phase I Trial
IMP761 LAG-3 agonist met safety goals in Phase I trial, showing statistically significant T-cell suppression in healthy volunteers at...
FDA Clears IND Amendment for MAIA’s Ateganosine Phase 2 NSCLC Trial Expansion
FDA clears IND amendment for MAIA's ateganosine Phase 2 NSCLC trial expansion, targeting third-line patients with durable survival signals.
Dapirolizumab Pegol Shows Steroid-Sparing Benefit in Phase 3 SLE Trial
Dapirolizumab pegol achieved steroid-sparing benefit in Phase 3 SLE trial, enabling patients to taper glucocorticoids while maintaining disease control.
Zenagamtide achieves 89% A1C target with 14.6% weight loss in diabetes trial
Zenagamtide diabetes trial shows 89% of participants reached A1C targets with 14.6% weight loss in phase 2 study.
Aleniglipron’s Phase 2b Data Redraws the Oral GLP-1 Efficacy Map — And Raises Hard Questions for Phase 3 Design
Structure Therapeutics' aleniglipron hit 14.7% weight loss in Phase 2b, matching injectable benchmarks. Here's what the trial design signals...
China’s Tenecteplase Trial Just Challenged the Global Stroke Playbook — and the FDA Should Be Paying Attention
A phase 3 RCT from China finds tenecteplase before EVT cuts disability in proximal MCA occlusion strokes 4.5–24 hrs...
TG Therapeutics’ Subcutaneous BRIUMVI Meets Phase 1 Bioavailability Goals
TG Therapeutics' subcutaneous BRIUMVI achieves bioavailability goals in Phase 1, potentially offering quarterly dosing for relapsing multiple sclerosis.